Drug intelligence / Profile preview

TauTX

Development stage: Unknown
Lead developer: TauRx Therapeutics
Modality: Small Molecules
Administration: Oral

Overview

TauTX is a small molecule modulator designed to target tau protein aggregation. It was developed by Chord Therapeutics, a company focused on rare neurological disorders, and was in Phase 1 development for progressive supranuclear palsy and other tauopathies. Merck KGaA acquired Chord Therapeutics, integrating TauTX into its neurology pipeline to address unmet needs in rare diseases.

Targets

MAPT (Microtubule-associated protein tau)

Beyond the preview

Go deeper on TauTX.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TauTX.

Explore the full profile